CBB1007 (hydrochloride)

CBB1007 hydrochloride is a reversible and selective LSD1 inhibitor with an IC50 of 5.27 µM for human LSD1. CBB1007 hydrochloride significantly blocks the demethylase activity of LSD1 on H3K4Me2 and H3K4Me. CBB1007 hydrochloride shows selectivity for LSD1 over LSD2 or JARID1A, and induces differentiation-related genes in pluripotent cells. CBB1007 hydrochloride is studied in  non-pluripotent cancer research, targeting teratocarcinoma, embryonic carcinoma, and seminoma[1][2].

Product Specifications

CAS Number

[2070014-96-7]

UNSPSC

12352005

Target

Histone Demethylase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/CBB1007-hydrochloride.html

Purity

98.0

Solubility

10 mM in DMSO

Smiles

[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.NC(N1CCN(CC1)CC2=CC(C(OC)=O)=CC(C(N3CCN(CC3)C(C4=CC=C(C=C4)C(N)=N)=O)=O)=C2)=N

Molecular Formula

C27H39Cl5N8O4

Molecular Weight

716.91

References & Citations

[1]Xiong Y, et al. Inhibition of Lysine-Specific Demethylase-1 (LSD1/KDM1A) Promotes the Adipogenic Differentiation of hESCs Through H3K4 Methylation. Stem Cell Rev Rep. 2016;12 (3) :298-304.|[2]Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011;71 (23) :7238-7249.